Peter A. Thompson - Sep 17, 2021 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC. (ALPN)

Role: Director, 10%+ Owner
Signature: /s/ Peter Thompson
Stock symbol: ALPN
Transactions as of: Sep 17, 2021
Transactions value $: $9,499,988
Form type: 4
Date filed: 9/21/2021, 06:38 PM
Previous filing: Sep 13, 2021
Next filing: Sep 22, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALPN	Common Stock	Purchase	$5.5M	+585K	+19.05%	$9.40	3.66M	Sep 17, 2021	See Footnotes	F1, F2, F4
transaction	ALPN	Common Stock	Purchase	$4M	+426K		$9.40	426K	Sep 17, 2021	See Footnotes	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of the Issuer's common stock were purchased in a block order at a price of $9.40.
F2	These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is an employee of Advisors. Advisors and GP VI exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.
F3	These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and Advisors is the managing member of Genesis GP. Advisors and Genesis GP exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund.
F4	Each of GP VI, Advisors, Genesis GP, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.